Toll Free: 1-888-928-9744

Emphysema - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Emphysema - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Emphysema - Pipeline Review, H2 2016, provides an overview of the Emphysema (Respiratory) pipeline landscape.

Emphysema is a type of COPD involving damage to the alveoli in the lungs. Symptoms include shortness of breath and cough with sputum. Risk factors include age, smoking, exposure to air pollutions, factory fumes, coal and silica dust. Treatment includes bronchodilators, antibiotics and steroids. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Emphysema - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Emphysema (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Emphysema (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Emphysema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 8 and 1 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively for Emphysema.

Emphysema (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Emphysema (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Emphysema (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Emphysema (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Emphysema (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Emphysema (Respiratory)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Emphysema (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Emphysema (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Emphysema Overview 6 Therapeutics Development 7 Pipeline Products for Emphysema - Overview 7 Pipeline Products for Emphysema - Comparative Analysis 8 Emphysema - Therapeutics under Development by Companies 9 Emphysema - Therapeutics under Investigation by Universities/Institutes 10 Emphysema - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Emphysema - Products under Development by Companies 13 Emphysema - Products under Investigation by Universities/Institutes 14 Emphysema - Companies Involved in Therapeutics Development 15 Angion Biomedica Corp. 16 ProMetic Life Sciences Inc. 17 rEVO Biologics, Inc. 18 SATT North SAS 19 TGV-Laboratories 20 Emphysema - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 alpha-1 proteinase inhibitor (human) - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 alpha-1 proteinase inhibitor (human) - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Antibody for Emphysema - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 BB-3 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 EDO-66 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 MG-53 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Monoclonal Antibody to Inhibit EMAP II for Emphysema - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Mul-1867 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Peptide to Inhibit Beta Galactosidase for Pulmonary Emphysema - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Recombinant Human Alpha-1 Antitrypsin - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 TM-5441 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Emphysema - Dormant Projects 45 Emphysema - Discontinued Products 46 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 47 Disclaimer 48
List of Tables
Number of Products under Development for Emphysema, H2 2016 7 Number of Products under Development for Emphysema - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Products under Investigation by Universities/Institutes, H2 2016 14 Emphysema - Pipeline by Abeona Therapeutics, Inc. , H2 2016 15 Emphysema - Pipeline by Angion Biomedica Corp., H2 2016 16 Emphysema - Pipeline by ProMetic Life Sciences Inc., H2 2016 17 Emphysema - Pipeline by rEVO Biologics, Inc., H2 2016 18 Emphysema - Pipeline by SATT North SAS, H2 2016 19 Emphysema - Pipeline by TGV-Laboratories, H2 2016 20 Assessment by Monotherapy Products, H2 2016 21 Number of Products by Stage and Target, H2 2016 23 Number of Products by Stage and Mechanism of Action, H2 2016 25 Number of Products by Stage and Route of Administration, H2 2016 27 Number of Products by Stage and Molecule Type, H2 2016 29 Emphysema - Dormant Projects, H2 2016 45 Emphysema - Discontinued Products, H2 2016 46



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify